Mário Sérgio Póvoa Correia

Mr. Mário Sérgio Póvoa Correia

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
NGNeeraj Garg
Neeraj Garg
LCLouis P. Conway
Louis P. Conway
CBCaroline Ballet
Caroline Ballet
MCMário Sérgio Póvoa Correia
Mário Sérgio Póvoa Correia
FOFrida K. S. Olsson
Frida K. S. Olsson
Daniel GlobischDaniel Globisch
Daniel Globisch

28 June 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
CBCaroline Ballet
Caroline Ballet
MCMário Sérgio Póvoa Correia
Mário Sérgio Póvoa Correia
LCLouis P. Conway
Louis P. Conway
TLTheresa L. Locher
Theresa L. Locher
LLLaura C. Lehmann
Laura C. Lehmann
Daniel GlobischDaniel Globisch
Daniel Globisch
Gut microbiota significantly impact human physiology through metabolic interaction. Selective investigation of the co-metabolism of bacteria and their human host is a challenging task and methods for their analysis are limited. One class of metabolites associated with this co-metabolism are O-sulfated compounds. Herein, we describe the development of a new enzymatic assay for the selective mass spectrometric investigation of this phase II modification class. Analysis of human urine and fecal samples resulted in the detection of 206 sulfated metabolites, which is three times more than reported in the Human Metabolome Database. We confirmed the chemical structure of 36 sulfated metabolites including unknown and commonly reported microbiota-derived sulfated metabolites using synthesized internal standards and mass spectrometric fragmentation experiments. Our findings demonstrate that enzymatic sample pre-treatment combined with state-of-the-art metabolomics analysis represents a new and efficient strategy for the discovery of unknown microbiota-derived metabolites in human samples. Our described approach can be adapted for the targeted investigation of other metabolite classes as well as the discovery of biomarkers for diseases affected by microbiota.

22 July 2021 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
PDF file
TVTheodosia Vallianatou
Theodosia Vallianatou
WLWeifeng Lin
Weifeng Lin
NBNicholas B Bèchet
Nicholas B Bèchet
MCMário Sérgio Póvoa Correia
Mário Sérgio Póvoa Correia
NSNagesh C Shanbhag
Nagesh C Shanbhag
Daniel GlobischDaniel Globisch
Daniel Globisch
Sleep has evolved as a universal core function to allow for restorative biological processes. Detailed knowledge of metabolic changes necessary for the sleep state in the brain is missing. Herein, we have performed an in-depth metabolic analysis of four mouse brain regions and uncovered region-specific circadian variations. Metabolites linked to oxidative stress were altered during sleep including acylcarnitines, hydroxylated fatty acids, phenolic compounds, and thiol-containing metabolites. These findings provide molecular evidence of a significant metabolic shift of the brain energy metabolism. Specific alterations were observed for brain metabolites that have previously not been associated with a circadian function including the microbiome-derived metabolite ergothioneine that suggests a regulatory function. The pseudopeptide β-citryl-glutamate has been linked to brain development and we have now discovered a previously unknown regioisomer. These metabolites altered by the circadian rhythm represent the foundation for hypothesis-driven studies of the underlying metabolic processes and their function.

4 June 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
LCLouis P. Conway
Louis P. Conway
VRVeronica Rendo
Veronica Rendo
MCMário Sérgio Póvoa Correia
Mário Sérgio Póvoa Correia
IBIngvar A. Bergdahl
Ingvar A. Bergdahl
TSTobias Sjöblom
Tobias Sjöblom
Daniel GlobischDaniel Globisch
Daniel Globisch
N‐Acetyltransferases play critical roles in the deactivation and clearance of xenobiotics, including clinical drugs. NAT2 has been classified as an arylamine N‐acetyltransferase that mainly converts aromatic amines, hydroxylamines, and hydrazines. Herein, we demonstrate that the human arylamine N‐acetyltransferase NAT2 also acetylates aliphatic endogenous amines. Metabolomic analysis and chemical synthesis revealed increased intracellular concentrations of mono‐ and diacetylated spermidine in human cell lines expressing the rapid compared to the slow acetylator NAT2 phenotype. The regioselective N8‐acetylation of monoacetylated spermidine by NAT2 answers the long‐standing question of the source of diacetylspermidine. We also identified selective acetylation of structurally diverse alkylamine‐containing drugs by NAT2, which may contribute to variations in patient responses. The results demonstrate a previously unknown functionality and potential regulatory role for NAT2, and we suggest that this enzyme should be considered for re‐classification.

1 November 2020 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
MCMário Sérgio Póvoa Correia
Mário Sérgio Póvoa Correia
AJAbhishek Jain
Abhishek Jain
WAWafa Alotaibi
Wafa Alotaibi
PYPaul Young Tie Yang
Paul Young Tie Yang
AAna Rodriguez-Mateos
Ana Rodriguez-Mateos
Daniel GlobischDaniel Globisch
Daniel Globisch
The gut microbiome converts dietary compounds that are absorbed in the gastrointestinal tract and further metabolized by the human host. Sulfated metabolites are a major compound class derived from this co-metabolism and have been linked to disease development. In the present multidisciplinary study, we have investigated human urine samples from a dietary intervention study with 22 individuals collected before and after consumption of a polyphenol rich breakfast. These samples were analyzed utilizing our method combining enzymatic metabolite hydrolysis using an arylsulfatase and mass spectrometric metabolomics. Key to this study is the validation of 235 structurally diverse sulfated metabolites. We have identified 48 significantly upregulated metabolites upon dietary intervention including 11 previously unknown sulfated metabolites for this diet. We observed a large variation in subjects based on their potential to sulfate metabolites, which may be the foundation for classification of subjects as high and low sulfate metabolizers in future large cohort studies. The reported sulfatase-based method is a robust tool for the discovery of unknown microbiota-derived metabolites in human samples.

26 May 2024 in Gut Microbes
Verified
Journal Article
Open access
LCLiqin Cheng
Liqin Cheng
MCMário Sérgio Póvoa Correia
Mário Sérgio Póvoa Correia
SHShawn Higdon
Shawn Higdon
FGFabricio Romero Garcia
Fabricio Romero Garcia
ITIoanna Tsiara
Ioanna Tsiara
Juan DuJuan Du
Juan Du
Multidrug-resistant microorganisms have become a major public health concern around the world. The gut microbiome is a gold mine for bioactive compounds that protect the human body from pathogens. We used a multi-omics approach that integrated whole-genome sequencing (WGS) of 74 commensal gut microbiome isolates with metabolome analysis to discover their metabolic interaction with Salmonella and other antibiotic-resistant pathogens. We evaluated differences in the functional potential of these selected isolates based on WGS annotation profiles. Furthermore, the top altered metabolites in co-culture supernatants of selected commensal gut microbiome isolates were identified including a series of dipeptides and examined for their ability to prevent the growth of various antibiotic-resistant bacteria. Our results provide compelling evidence that the gut microbiome produces metabolites, including the compound class of dipeptides that can potentially be applied for anti-infection medication, especially against antibiotic-resistant pathogens. Our established pipeline for the discovery and validation of bioactive metabolites from the gut microbiome as novel candidates for multidrug-resistant infections represents a new avenue for the discovery of antimicrobial lead structures.